<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:40:16Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8378741" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8378741</identifier>
        <datestamp>2021-08-21</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8378741</article-id>
              <article-id pub-id-type="pmcid">PMC8378741</article-id>
              <article-id pub-id-type="pmc-uid">8378741</article-id>
              <article-id pub-id-type="pmid">34415933</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-21-06961</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Population Groupings</subject>
                    <subj-group>
                      <subject>Age Groups</subject>
                      <subj-group>
                        <subject>Children</subject>
                        <subj-group>
                          <subject>Infants</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>People and Places</subject>
                  <subj-group>
                    <subject>Population Groupings</subject>
                    <subj-group>
                      <subject>Families</subject>
                      <subj-group>
                        <subject>Children</subject>
                        <subj-group>
                          <subject>Infants</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                      <subj-group>
                        <subject>Antiviral Therapy</subject>
                        <subj-group>
                          <subject>Antiretroviral Therapy</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Vaccination and Immunization</subject>
                      <subj-group>
                        <subject>Antiviral Therapy</subject>
                        <subj-group>
                          <subject>Antiretroviral Therapy</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Public and Occupational Health</subject>
                    <subj-group>
                      <subject>Preventive Medicine</subject>
                      <subj-group>
                        <subject>Vaccination and Immunization</subject>
                        <subj-group>
                          <subject>Antiviral Therapy</subject>
                          <subj-group>
                            <subject>Antiretroviral Therapy</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Immunodeficiency Viruses</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Immunodeficiency Viruses</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral Pathogens</subject>
                        <subj-group>
                          <subject>Immunodeficiency Viruses</subject>
                          <subj-group>
                            <subject>HIV</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Immunodeficiency Viruses</subject>
                        <subj-group>
                          <subject>HIV</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and life sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>RNA viruses</subject>
                        <subj-group>
                          <subject>Retroviruses</subject>
                          <subj-group>
                            <subject>Lentivirus</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Microbiology</subject>
                    <subj-group>
                      <subject>Medical Microbiology</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Retroviruses</subject>
                            <subj-group>
                              <subject>Lentivirus</subject>
                              <subj-group>
                                <subject>HIV</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Pathogens</subject>
                      <subj-group>
                        <subject>Microbial Pathogens</subject>
                        <subj-group>
                          <subject>Viral Pathogens</subject>
                          <subj-group>
                            <subject>Retroviruses</subject>
                            <subj-group>
                              <subject>Lentivirus</subject>
                              <subj-group>
                                <subject>HIV</subject>
                              </subj-group>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Organisms</subject>
                    <subj-group>
                      <subject>Viruses</subject>
                      <subj-group>
                        <subject>Viral Pathogens</subject>
                        <subj-group>
                          <subject>Retroviruses</subject>
                          <subj-group>
                            <subject>Lentivirus</subject>
                            <subj-group>
                              <subject>HIV</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Women's Health</subject>
                    <subj-group>
                      <subject>Maternal Health</subject>
                      <subj-group>
                        <subject>Breast Feeding</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pediatrics</subject>
                    <subj-group>
                      <subject>Neonatology</subject>
                      <subj-group>
                        <subject>Breast Feeding</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Rheumatology</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Physiological Parameters</subject>
                      <subj-group>
                        <subject>Body Weight</subject>
                        <subj-group>
                          <subject>Birth Weight</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drug Research and Development</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Science Policy</subject>
                  <subj-group>
                    <subject>Research Integrity</subject>
                    <subj-group>
                      <subject>Research Ethics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial</article-title>
                <alt-title alt-title-type="running-head">Postnatal infant growth in the PROMISE trial</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3566-1688</contrib-id>
                  <name>
                    <surname>Stranix-Chibanda</surname>
                    <given-names>Lynda</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Investigation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tierney</surname>
                    <given-names>Camlin</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pinilla</surname>
                    <given-names>Mauricio</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>George</surname>
                    <given-names>Kathleen</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4408-8839</contrib-id>
                  <name>
                    <surname>Aizire</surname>
                    <given-names>Jim</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="aff006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chipoka</surname>
                    <given-names>Godwin</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mallewa</surname>
                    <given-names>Macpherson</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff008" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Naidoo</surname>
                    <given-names>Megeshinee</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff009" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nematadzira</surname>
                    <given-names>Teacler</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kusakara</surname>
                    <given-names>Bangani</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Violari</surname>
                    <given-names>Avy</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff010" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mbengeranwa</surname>
                    <given-names>Tapiwa</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Njau</surname>
                    <given-names>Boniface</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff011" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5327-1734</contrib-id>
                  <name>
                    <surname>Fairlie</surname>
                    <given-names>Lee</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff012" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Theron</surname>
                    <given-names>Gerard</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff013" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mubiana-Mbewe</surname>
                    <given-names>Mwangelwa</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff014" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Khadse</surname>
                    <given-names>Sandhya</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff015" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Browning</surname>
                    <given-names>Renee</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff016" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fowler</surname>
                    <given-names>Mary Glenn</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff017" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5999-1596</contrib-id>
                  <name>
                    <surname>Siberry</surname>
                    <given-names>George K.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff018" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>for the PROMISE Study Team</collab>
                  <xref rid="fn001" ref-type="author-notes">
                    <sup>¶</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>University of Zimbabwe Faculty of Medicine and Health Sciences, Child and Adolescent Health Unit, Harare, Zimbabwe</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research in the Department of Biostatistics, Boston, MA, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>FHI 360, Durham, NC, United States of America</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Makerere University—Johns Hopkins University Research Programme, Kampala, Uganda</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>University of North Carolina Project, Lilongwe, Malawi</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>College of Medicine—Johns Hopkins University Project, Blantyre, Malawi</addr-line>
              </aff>
              <aff id="aff009">
                <label>9</label>
                <addr-line>University of KwaZulu-Natal, Centre Aids Prevention Research South Africa (CAPRISA), Durban, South Africa</addr-line>
              </aff>
              <aff id="aff010">
                <label>10</label>
                <addr-line>Perinatal HIV Research Unit, Johannesburg, South Africa</addr-line>
              </aff>
              <aff id="aff011">
                <label>11</label>
                <addr-line>Kilimanjaro Christian Medical Center, Moshi, United Republic of Tanzania</addr-line>
              </aff>
              <aff id="aff012">
                <label>12</label>
                <addr-line>Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa</addr-line>
              </aff>
              <aff id="aff013">
                <label>13</label>
                <addr-line>Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa</addr-line>
              </aff>
              <aff id="aff014">
                <label>14</label>
                <addr-line>Centre for Infectious Disease Research in Zambia, Lusaka, Zambia</addr-line>
              </aff>
              <aff id="aff015">
                <label>15</label>
                <addr-line>Department of Obstetrics and Gynaecology, BJ Government Medical College, Pune, India</addr-line>
              </aff>
              <aff id="aff016">
                <label>16</label>
                <addr-line>Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States of America</addr-line>
              </aff>
              <aff id="aff017">
                <label>17</label>
                <addr-line>Johns Hopkins University School of Medicine, Baltimore, MD, United States of America</addr-line>
              </aff>
              <aff id="aff018">
                <label>18</label>
                <addr-line>Office of HIV/AIDS, United States Agency for International Development, Washington, DC, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>De Socio</surname>
                    <given-names>Giuseppe Vittorio</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Azienda Ospedaliera Universitaria di Perugia, ITALY</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <fn fn-type="other" id="fn001">
                  <p>¶ Complete membership of the author group can be found in the Acknowledgments</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>lstranix@uz-ctrc.org</email>, <email>stranixchibanda@gmail.com</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>16</volume>
              <issue>8</issue>
              <elocation-id>e0255250</elocation-id>
              <history>
                <date date-type="received">
                  <day>3</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>4</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="cc0license">https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref>
                  <license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0255250.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Malnutrition is highly prevalent in HIV-exposed perinatally uninfected infants (HEUs) increasing the risk of morbidity and mortality throughout the life course. We set out to compare the effect of postnatal exposure to maternal antiretroviral therapy (mART) in breastmilk versus infant Nevirapine prophylaxis (iNVP) on somatic growth of HEUs in the randomized PROMISE trial.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods and findings</title>
                  <p>We randomized 2431 mothers with HIV and their 2444 HEUs from six African countries and India 6–14 days after delivery to mART or iNVP for prevention of breastmilk HIV transmission. The mART regimen contained tenofovir/emtricitabine (99%) plus lopinavir/ritonavir. Infant growth parameters were compared at postnatal week 10, 26, 74 and 104 using World Health Organization (WHO) z-scores for length-for-age (LAZ), weight-for-age (WAZ), and head circumference-for-age (HCAZ). Week 26 LAZ was the primary endpoint measure. Student T-tests compared mean LAZ, WAZ, and HCAZ; estimated mean and 95% confidence interval (CI) are presented.</p>
                  <p>Maternal and infant baseline characteristics were comparable between study arms. The estimated median breastfeeding duration was 70 weeks. After a mean follow-up of 88 weeks, mean LAZ and WAZ were below the WHO reference population mean at all timepoints, whereas mean HCAZ was not. The mART and iNVP arms did not differ for the primary outcome measure of LAZ at week 26 (p-value = 0.39; estimated mean difference (95%CI) of -0.05 (-0.18, 0.07)) or any of the other secondary growth outcome measures or timepoints (all p-values≥0.16). Secondary analyses of the primary outcome measure adjusting for week 0 LAZ and other covariates did not change these results (all p-values≥0.09). However, infants assigned to mART were more likely to have stunting compared to iNVP infants at week 26 (odds ratio (95% CI): 1.28 (1.05, 1.57)).</p>
                </sec>
                <sec id="sec003">
                  <title>Conclusions</title>
                  <p>In HEUs, growth effects from postnatal exposure to mART compared to iNVP were comparable for measures on length, weight and head circumference with no clinically relevant differences between the groups. Despite breastfeeding into the second year of life, length and weight were below reference population means at all ages in both arms. Further investment is needed to optimize postnatal growth of infants born to women with HIV.</p>
                </sec>
                <sec id="sec004">
                  <title>Clinical trial registration</title>
                  <p>ClinicalTrials.gov number <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01061151" ext-link-type="uri">NCT01061151</ext-link>.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100009633</institution-id>
                      <institution>eunice kennedy shriver national institute of child health and human development</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>co-funder</award-id>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>national institute of mental health</institution>
                  </funding-source>
                  <award-id>co-funder</award-id>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UM1AI068632</award-id>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UM1AI068616</award-id>
                </award-group>
                <award-group id="award005">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UM1AI106716</award-id>
                </award-group>
                <award-group id="award006">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000071</institution-id>
                      <institution>National Institute of Child Health and Human Development</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HHSN275201800001I</award-id>
                </award-group>
                <funding-statement>Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the National Institutes of Health (NIH), under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), and by NICHD contract number HHSN275201800001I. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="2"/>
                <page-count count="15"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>The individual level data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon request to the IMPAACT Statistical and Data Management Centre’s data access committee by email to <email>sdac.data@fstrf.org</email> or <email>sdac.data@sdac.harvard.edu</email>. This committee reviews and responds to requests for data, obtains necessary approvals from IMPAACT leadership and the NIH, arranges for signature of a Data Use Agreement, and releases the requested data.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>The individual level data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon request to the IMPAACT Statistical and Data Management Centre’s data access committee by email to <email>sdac.data@fstrf.org</email> or <email>sdac.data@sdac.harvard.edu</email>. This committee reviews and responds to requests for data, obtains necessary approvals from IMPAACT leadership and the NIH, arranges for signature of a Data Use Agreement, and releases the requested data.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>Prior research suggests that HIV-exposed uninfected infants (HEUs) have diminished somatic growth compared to unexposed infants [<xref rid="pone.0255250.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0255250.ref005" ref-type="bibr">5</xref>]. Wasting, stunting and underweight more than double the hazard of childhood mortality [<xref rid="pone.0255250.ref006" ref-type="bibr">6</xref>–<xref rid="pone.0255250.ref008" ref-type="bibr">8</xref>] while their early life effect on neurocognition diminishes developmental potential in adult life [<xref rid="pone.0255250.ref009" ref-type="bibr">9</xref>]. The relative contributions of advanced maternal HIV disease, restricted breastfeeding and antiretroviral (ARV) drug exposures are not clear, leading to mixed conclusions in published literature about the effect of <italic toggle="yes">in utero</italic> ARV exposure on birth size and postnatal growth [<xref rid="pone.0255250.ref010" ref-type="bibr">10</xref>–<xref rid="pone.0255250.ref012" ref-type="bibr">12</xref>]. Previous guidelines for antiretroviral treatment (ART) reserved treatment for pregnant women with advanced HIV disease, itself a predictor of poor infant growth. Similarly, earlier recommendations to avoid or limit the duration of breastfeeding for infants exposed to HIV complicated evaluations of growth in infant populations where early cessation of breastfeeding or not breastfeeding increases infant mortality and morbidity, mostly in resource limited settings [<xref rid="pone.0255250.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0255250.ref014" ref-type="bibr">14</xref>]. The current recommendation in such settings is to provide life-long ART to pregnant women with HIV and to breastfeed [<xref rid="pone.0255250.ref015" ref-type="bibr">15</xref>], with many countries discouraging weaning before 2 years. The effect on growth of exposure to maternal ART (mART) throughout the first 1000 days of a child’s life (from conception through second birthday) is not well established.</p>
              <p>The postpartum randomization in the multi-country PROMISE trial provided an ideal opportunity to study postnatal growth in breastfed infants exposed to mART but not to advanced maternal HIV disease. Primary analyses of the relative safety and efficacy of the ARV strategies evaluated were previously published [<xref rid="pone.0255250.ref016" ref-type="bibr">16</xref>–<xref rid="pone.0255250.ref018" ref-type="bibr">18</xref>]. This secondary analysis assesses the effect of breastmilk exposure to mART on infant/child growth through 104 weeks of life compared to extended infant Nevirapine prophylaxis (iNVP), assessed by length-for-age (LAZ), weight-for-age (WAZ) and head circumference-for-age (HCAZ) z-scores.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Methods</title>
              <sec id="sec007">
                <title>Study design and participants</title>
                <p>PROMISE was a randomized open-label trial to evaluate the relative efficacy and safety of several proven ARV strategies to prevent vertical HIV transmission and optimize maternal health and child survival among healthy women who did not meet local criteria to initiate ART in settings with varying standards of care [<xref rid="pone.0255250.ref013" ref-type="bibr">13</xref>–<xref rid="pone.0255250.ref015" ref-type="bibr">15</xref>]. <xref rid="pone.0255250.g001" ref-type="fig">Fig 1</xref> presents the overall PROMISE trial schema in countries where maternal ART was not standard at the time, illustrating the three sequential PROMISE components; Antepartum, Postpartum and Maternal Health (<xref rid="pone.0255250.s002" ref-type="supplementary-material">S1 Fig</xref>). The Postpartum randomization for breastfeeding mother-infant pairs was conducted at 14 health facility-based research sites in seven countries: India, Malawi, South Africa, Tanzania, Uganda, Zambia and Zimbabwe.</p>
                <fig position="float" id="pone.0255250.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0255250.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Participant flow diagram.</title>
                    <p>There was no apparent difference in premature study discontinuation for reasons other than death; 23 in the mART arm (2% of 1,227 randomized) and 15 in the iNVP arm (1% of 1217) (p = 0.81). The median (Q1-Q3) follow-up in both arms was to 104 weeks of age (74–105), with a mean of 88 weeks. Most infants still breastfed (93.7% (95%CI: 92.6%, 94.6%)) at 26 weeks of age. The estimated median (Q1-Q3) duration of breastfeeding and, hence, postnatal ARV exposure was 70 weeks (56–82) and not different in both study arms. As previously reported [<xref rid="pone.0255250.ref016" ref-type="bibr">16</xref>], 14 breastfed infants acquired HIV infection during postnatal follow-up (7/1219 mother-infant pairs in the maternal ART arm and 7/1211in the infant NVP arm).</p>
                  </caption>
                  <graphic xlink:href="pone.0255250.g001" position="float"/>
                </fig>
                <p>Women were recruited with their uninfected infants to the Postpartum Component between 2011 and 2015 after completing the Antepartum Component or when first identified as HIV-infected during active labor (“late presenters”). Maternal inclusion criteria included the intent to breast feed, a CD4 count <underline>&gt;</underline>350 cells/mm<sup>3</sup> at enrollment and above the country specific threshold for initiation of ART, hemoglobin ≥7.0 grams/dL, white blood cell count (WBC) ≥1500 cells/mm<sup>3</sup>, absolute neutrophil count (ANC) ≥750 cells/mm<sup>3</sup>, platelets ≥50,000 cells/mm<sup>3</sup>, alanine aminotransferase (ALT) ≤2.5x upper limit of normal, and estimated creatinine clearance of ≥60mL/min (Cockcroft-Gault equation for women). Inclusion criteria for infants included age ≤14 days, negative HIV nucleic acid test on a specimen drawn prior to the week 1 visit, hemoglobin ≥10 grams/dL, WBC ≥1,500 cells/mm<sup>3,</sup> ANC ≥750 cells/mm<sup>3</sup>, platelets ≥50,000 cells/mm<sup>3</sup>, and ALT ≤2.5x ULN. Mothers were excluded if they required ART for their own health. For multiple births, a mother-infant pair was enrolled only if all infants could be enrolled. Infants were excluded for life-threatening conditions or circumstances that would make long-term follow-up unlikely in the judgment of the site physician or when birthweight was &lt;2000g.</p>
              </sec>
              <sec id="sec008">
                <title>Randomizations</title>
                <p><italic toggle="yes">In utero</italic> ARV exposure for infants in the Postpartum Component differed by duration and regimen. At study entry in pregnancy, women with their unborn infant(s) were randomized to receive either prophylaxis with Zidovudine (plus single dose Nevirapine and a 1-week tail of Tenofovir/Emtricitabine) or triple ART (with Zidovudine/Lamivudine plus ritonavir boosted Lopinavir or Tenofovir/Emtricitabine plus ritonavir boosted Lopinavir) from the time of registration at variable gestational ages. Women presenting late for antenatal care in labor or post-delivery received no prior ARVs.</p>
                <p>Mother-infant pairs were randomized in the Postpartum Component in a 1:1 ratio at 6–14 days post-delivery to mART with Tenofovir/Emtricitabine plus (preferred) Lopinavir-ritonavir or to iNVP using age-based daily NVP dosing (<xref rid="pone.0255250.g001" ref-type="fig">Fig 1</xref>). A web-based, central computer randomization system on the IMPAACT Data Management Center’s portal was used. The system used permuted block allocation with stratification by country and the antepartum/intrapartum maternal ARV prophylaxis. A site staff member enrolled participants by answering eligibility and stratification questions in the randomization system, and if passed, the system randomized the participant and generated a coded study identification number which the site pharmacist compared to a master list and dispensed the corresponding study drug.</p>
                <p>In the Postpartum Component, the randomly assigned postpartum ARV regimen (mART or iNVP) was continued for the duration of breastfeeding plus 42 days (two weeks following breastfeeding cessation, defined as no breastmilk exposure for &gt;28 days) or through age 18 months, whichever came first, unless stopped for infant HIV infection, toxicity or other medical reason. All study infants received standard-of-care iNVP during the first six weeks of life and cotrimoxazole prophylaxis thereafter, per local guidelines.</p>
                <p>On July 6, 2015 PROMISE sites were notified that all maternal participants should be offered life-long ART for their health based on the results of the Strategic Timing of AntiRetroviral Treatment (START) study [<xref rid="pone.0255250.ref019" ref-type="bibr">19</xref>] which demonstrated a significant benefit to beginning ART early, including in those with high CD4 counts. Analyses are thus based on data collected at visits through the date of notification.</p>
              </sec>
              <sec id="sec009">
                <title>Growth monitoring</title>
                <p>Length, weight and head circumference were measured by trained study personnel using standard methods at birth and weeks 1, 6, 10, 14, 26, 38, 50, 62, 74, 86, 98 and 104 of life. Measurements of length and weight were performed using standardized rigid length boards and calibrated weighing scales. Mothers received infant feeding counselling throughout the study and were supported to breastfeed exclusively for the first six months of life followed by the gradual introduction of appropriate foods and fluids. The timing of cessation of breastfeeding was determined by the mother. Breastfeeding status and infant illnesses were recorded at each visit. The full PROMISE 1077BF protocol can be accessed on the protocol website at <ext-link xlink:href="https://www.impaactnetwork.org/studies/1077BF.asp" ext-link-type="uri">https://www.impaactnetwork.org/studies/1077BF.asp</ext-link>.</p>
              </sec>
              <sec id="sec010">
                <title>Study oversight</title>
                <p>The study was funded by the National Institutes of Health (ClinicalTrials.gov number NCT01061151). Written informed consent was obtained from each maternal study participant for her and her child’s participation. Study conduct adhered to international guidelines and was reviewed every six months by an independent Data and Safety Monitoring Board. Ethics committees and institutional review boards that approved this study include—MUJHU/Kampala, Uganda: The Joint Clinical Research Centre (JCRC) IRB, the National Drug Authority and the Uganda National Council of Science and Technology (UNCST) in Uganda and the Johns Hopkins Medical Institutions (JHMI) IRB in the U.S.; Wits RHI Shandukani CRS and Soweto IMPAACT CRS, Johannesburg, South Africa: University of Witwatersrand Human Ethics Research Committee (Medical), Medicines Control Council (South African Health Products Regulatory Authority in February 2018); FAM-CRU CRS, Cape town, South Africa: Health Research Ethics Committee (HREC), Faculty of Health Sciences, Stellenbosch University and Medicines Control Council (South African Health Products Regulatory Authority in February 2018); Durban Paediatric HIV CRS, Durban, South Africa: University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee, Medicines Control Council (South African Health Products Regulatory Authority in February 2018); George CRS, Lusaka, Zambia: University of North Carolina (UNC) at Chapel Hill Biomedical IRB and University of Zambia Biomedical Research Ethics Committee (UNZABREC); Harare, Seke North and St. Mary’s sites, Zimbabwe: Medical Research Council of Zimbabwe(MRCZ), Research Council of Zimbabwe (RCZ), Medicine Control Authority of Zimbabwe (MCAZ), Joint Parirenyatwa group of Hospitals/University of Zimbabwe College of Health Sciences Research Ethics Committee(JREC); Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, India: BJ Government College CTU Ethics Committee and Johns Hopkins IRB; Blantyre, Malawi: College of Medicine Research and Ethics Committee (COMREC) in Malawi, Pharmacy, Medicines and Poisons Board and Johns Hopkins Medical Institutions (JHMI) IRB in the U.S.; Lilongwe, Malawi: National Health Sciences Research Committee (NHSRC) in Malawi Pharmacy, Medicines and Poisons Board, and University of North Carolina, Chapel Hill (UNC-CH) Office of Human Research Ethics IRB in the U.S and Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania: Kilimanjaro Christian Medical College Ethics Committee, National Health Research Ethics Committee and Tanzania Medicines and Medical Devices Authority.</p>
              </sec>
              <sec id="sec011">
                <title>Statistical methods</title>
                <p>Age and sex-appropriate World Health Organization z-scores were computed for LAZ, WAZ and HCAZ based on the SAS macro for z-score calculations for children aged &lt;61 months [<xref rid="pone.0255250.ref020" ref-type="bibr">20</xref>]. The primary objective comparison timepoint was Week 26 and primary outcome measure was LAZ at Week 26; LAZ at weeks 10, 74, and 104, as well as WAZ and HCAZ at weeks 10, 26, 74, and 104 were secondary outcome measures. Mean z-scores for each anthropometric measure were compared at these timepoints between the assigned study arms—mART versus iNVP. Primary analyses were carried out using an intent to treat approach (analyzed as randomized), as were secondary analyses on additional growth outcome measures. Selected subgroup and restricted/as-treated analyses were performed as secondary analyses. Except for accrual and baseline summaries the unit of analysis was the infant. Twins were analyzed separately.</p>
                <p>Mean age adjusted z-scores were compared with a Student’s t-test. Modification of the mART versus iNVP effect by subgroups (interaction tests) were assessed via linear regression. Comparisons of other data applied Wilcoxon/Kruskal-Wallis for continuous data, <italic toggle="yes">X</italic><sup>2</sup>/exact tests for categorical data, as appropriate. Treatment effects for binary outcomes were summarized with odds ratios from logistic regression. P-values and tests were two-sided and nominal with a significance level set at 0.05. The z-scores were also compared for LAZ stunting, WAZ underweight and HCAZ using a binary categorization with the following standard deviation (SD) cut offs: z-score &lt; -2 SD and ≥-2 SD [<xref rid="pone.0255250.ref021" ref-type="bibr">21</xref>].</p>
                <p>The individual level data cannot be made publicly available due to the ethical restrictions in the study’s informed consent documents and in the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’s approved human subjects protection plan; public availability may compromise participant confidentiality. However, data are available to all interested researchers upon request to the IMPAACT Statistical and Data Management Centre’s data access committee by email to <email>sdac.data@fstrf.org</email> or <email>sdac.data@sdac.harvard.edu</email>. This committee reviews and responds to requests for data, obtains necessary approvals from IMPAACT leadership and the NIH, arranges for signature of a Data Use Agreement, and releases the requested data.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec012">
              <title>Results</title>
              <sec id="sec013">
                <title>Accrual and analysis inclusion</title>
                <p>A total of 2431 mother-infant pairs were randomized in the Postpartum Component, with 1220 pairs in the mART and 1211 in the iNVP arms. A total of 128 (5%) pairs had received no ARVs prior to the onset of labor and entered as Late Presenters. For those previously enrolled in the Antepartum Component, 1009 pairs (42%) had been randomly assigned during pregnancy to <italic toggle="yes">in utero</italic> Zidovudine prophylaxis, 1005 pairs (41%) to <italic toggle="yes">in utero</italic> Zidovudine/Lamivudine plus ritonavir boosted Lopinavir and 289 pairs (12%) to Tenofovir/Emtricitabine plus ritonavir boosted Lopinavir.</p>
              </sec>
              <sec id="sec014">
                <title>Baseline characteristics</title>
                <p>Mothers enrolled were predominantly black African women (97%) of median (IQR) age 26.6 years (23.2–30.3) at the time of postpartum randomization and in good health; median (Q1-Q3) BMI 24.7 kg/m<sup>2</sup> (22.3–28.0), pre-ART CD4 count 535 cells/mm<sup>3</sup> (438–671) and 60% had viral load that was below the lower limit of quantification (36%) or quantifiable and &lt;400 copies/mL (24%). Infants were 51% male, had a median (Q1-Q3) birthweight of 2900g (2600–3200) and gestational age of 39 weeks (38–40). All infants were breastfed from birth. In the mART and iNVP arms respectively, there were seven and six pairs of twins (0.5% of the sample) and 143 infants in each arm (12%) were born prematurely, before 37 completed weeks of gestation. Maternal and infant baseline characteristics were comparable between study arms (<xref rid="pone.0255250.t001" ref-type="table">Table 1</xref>).</p>
                <table-wrap position="float" id="pone.0255250.t001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0255250.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Baseline characteristics for maternal and infant participants in the Postpartum Component.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0255250.t001" id="pone.0255250.t001g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1"/>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">PP Randomization Arm</th>
                        </tr>
                        <tr>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1"/>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Maternal ART (mART)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Infant Nevirapine Prophylaxis (iNVP)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Maternal Characteristics</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N = 1220</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N = 1211</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Age at randomization (years)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">18.4–43.5</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">18.3–46.6</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.7 (23.2–30.4)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.5 (23.1–30.3)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">27.2 (5.2)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">27.0 (5.1)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">20.8–34.5</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">20.7–34.3</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Race</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Asian (from Indian subcontinent)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0 (0%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2 (0%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Black African</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,178 (97%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,168 (96%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Indian (Native of India)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">41 (3%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">40 (3%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Coloured</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    AP Randomization/Late Presenter</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Late Presenter</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">66 (5%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">62 (5%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Triple ARV (3TC-ZDV/LPV-RTV)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">508 (42%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">497 (41%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Triple ARV (FTC-TDF/LPV-RTV)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">140 (11%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">149 (12%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">ZDV+sdNVP+TRV tail</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">506 (41%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">503 (42%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Weight (kg)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">35.0–121.9</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">35.4–133.0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">61.0 (54.9–69.8)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">61.0 (54.7–69.1)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">63.5 (12.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">62.9 (11.9)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">49.8–80.4</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">49.6–78.3</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Height (cm)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">131.4–180.0</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">117–179</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">158.0 (153.0–162.1)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">158.0 (152.3–162.0)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">157.6 (7.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">157.1 (6.9)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">149–166</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">148.9–165.4</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    BMI (kg/m<sup>2</sup>)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">16.6–48.9</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">15.8–50.6</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24.7 (22.3–28.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24.7 (22.3–28.0)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">25.5 (4.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">25.5 (4.5)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">20.4–31.9</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">20.4–31.2</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Gestational Age at PROMISE entry (weeks)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">67</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">62</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">13.6–40.1</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">13.7–43.3</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.3 (21.4–30.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.3 (21.7–31.4)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.2 (6.3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">26.4 (6.2)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">17.6–35.1</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">17.7–34.6</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    CD4 at Postpartum screening (cells/mm<sup>3</sup>)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">351–2019</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">353–2353</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">682.5 (555.0–870.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">691 (550–868)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">734.9 (254.3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">738.7 (259.0)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">454–1070</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">457.5–1086.0</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    HIV RNA level prior to randomization (copies/mL)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Below lower limit of quantification (LLQ) of the assay</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">499 (41%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">379 (31%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">&lt;400</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">276 (23%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">296 (25%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">400–1000</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">136 (11%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">138 (11%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">1000- &lt;10000</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">194 (16%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">277 (23%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10000 - &lt;100000</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">91 (7%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">104 (9%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">100000 - &lt;200000</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (1%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">9 (1%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">&gt; = 200000</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">10 (1%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">5 (0%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    WHO stage prior to randomization</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Clinical stage I</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,174 (96%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,182 (98%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Clinical stage II</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">45 (4%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">28 (2%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Clinical stage III</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1 (0%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Infant Characteristics</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N = 1227</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N = 1217</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Sex</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Male</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">622 (51%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">614 (50%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Female</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">605 (49%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">603 (50%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Gestational Age at Birth (weeks)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">30–44</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">29.6–45.4</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">39 (38–40)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">39 (38–40)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">39.0 (2.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">38.9 (2.0)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">36–41</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">36–42</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Weight at Week 0 visit (0–5 days old) (gm)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">9</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2000–4500</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2000–4500</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2910 (2600–3230)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2900 (2600–3200)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2951.1 (442.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2920.3 (434.1)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2400–3520</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">2370–3500</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    Length at Week 0 visit (0–5 days old) (cm)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">21</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">23</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">37–59</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">36.4–58.0</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">48.6 (47.0–50.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">48.0 (46.5–50.0)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">48.5 (2.9)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">48.1 (2.7)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">45–52</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">45–51</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    LAZ at Week 0 visit (0–5 days old)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">22</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">24</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-6.89–5.19</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-7.00–4.65</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.71 (-1.56–0.00)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.82 (-1.71–0.03)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.70 (1.51)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.90 (1.45)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-2.42–1.02</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-2.66–0.90</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Not Stunted</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,018 (84%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">972 (81%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stunted</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">187 (16%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">221 (19%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    WAZ at Week 0 visit (0–5 days old)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">9</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-3.38–2.48</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-3.38–2.49</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.75 (-1.39–0.10)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.77 (-1.45–0.13)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.75 (0.98)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.82 (0.98)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.94–0.55</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-2.14–0.40</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Not Underweight</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,101 (90%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,066 (88%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Underweight</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">117 (10%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">145 (12%)</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">    HCAZ at Week 0 visit (0–5 days old)</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"># missing</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">21</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">25</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Min-Max</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-7.69–8.67</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-11.82–7.79</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Median (Q1-Q3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.02 (-0.82–0.87)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.02 (-0.82–0.79)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (s.d.)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.07 (1.30)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.09 (1.38)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">10%-90%</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.41–1.69</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.76–1.54</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ ≥-2</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,146 (95%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1,103 (93%)</td>
                        </tr>
                        <tr>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1"/>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ &lt; -2</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">60 (5%)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">89 (7%)</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><underline><italic toggle="yes">Abbreviations</italic></underline>: <italic toggle="yes">AP—Antepartum; ARV—antiretroviral drug; BMI—body mass index; cm—centimeters; FTC—emtracitabine; gm—grams; HCAZ—head circumference-for-age z-score; iNVP—infant nevirapine prophylaxis; kg—kilograms; LAZ—length-for-age z-score; LPV-RTV—ritonavir based lopinavir; m—meters; mART—maternal antiretroviral treatment; mL—milliliters; mm—millimeters; PP—Postpartum; Q1-Q3—interquartile range; s</italic>.<italic toggle="yes">d</italic>.<italic toggle="yes">—standard deviation; sdNVP—single-dose nevirapine; TDF—tenofovir diphosphate; TRV—truvada; ZDV—zidovudine; WAZ—weight-for-age z-score; 3TC—lamivudine; 10%-90%—10th to 90th percentile; %—percent</italic>.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec015">
                <title>Infant study status</title>
                <p>Among the 2444 infants, 816 (33%) were still on-study on July 6, 2015 when sites were notified of the START study results, 1383 (57%) had completed study follow-up or had their site closed (7 (&lt;0.5%) of the 1383) and 245 (10%) had prematurely discontinued follow-up (<xref rid="pone.0255250.g001" ref-type="fig">Fig 1</xref>).</p>
              </sec>
              <sec id="sec016">
                <title>Infant growth outcomes</title>
                <p>Summary statistics and comparisons for the infant growth measures and z-scores at the key follow-up time points of weeks 10, 26, 74 and 104 of age are presented in <xref rid="pone.0255250.t002" ref-type="table">Table 2</xref>.</p>
                <table-wrap position="float" id="pone.0255250.t002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0255250.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Summary statistics and comparisons of infant growth measurements by Postpartum Component randomization.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0255250.t002" id="pone.0255250.t002g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1"> </th>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">mART</th>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1">iNVP</th>
                          <th align="center" colspan="2" style="background-color:#FFFFFF" rowspan="1"> </th>
                        </tr>
                        <tr>
                          <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Study Week</th>
                          <th align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Outcome</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (SE)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">N</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean (SE)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">Mean Difference (95% CI)</th>
                          <th align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">p-value<xref rid="t002fn002" ref-type="table-fn"><sup>a</sup></xref></th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 10</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">LAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1158</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.19 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.22 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.02 (-0.10, 0.14)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.73</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">WAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1157</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.37 (0.03)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.35 (0.03)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.02 (-0.11, 0.07)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.66</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1158</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.13 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.10 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.03 (-0.09, 0.14)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.63</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 26</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">LAZ (Primary)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1150</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.90 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1162</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.85 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.05 (-0.18, 0.07)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.39</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">WAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1151</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.28 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1161</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.28 (0.03)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.00 (-0.09, 0.10)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.96</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1151</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.60 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1162</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.67 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.07 (-0.18, 0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.18</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 74</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">LAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">864</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.53 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">879</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.49 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.04 (-0.16, 0.08)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.51</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">WAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">864</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.49 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">878</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.47 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.01 (-0.12, 0.09)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.82</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">863</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.70 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">879</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.79 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.09 (-0.22, 0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.16</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 104</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">LAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">655</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.55 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-1.52 (0.05)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.03 (-0.17, 0.10)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.62</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">WAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">654</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.52 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.48 (0.04)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.04 (-0.15, 0.08)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.53</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">655</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.06 (0.06)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.14 (0.06)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">-0.08 (-0.26, 0.09)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.35</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold> </bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>mART</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold> </bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>iNVP</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Study Week</bold>
                          </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Outcome</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>n (%)</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>N</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>n (%)</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>Odds Ratio (95% CI)</bold>
                          </td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">
                            <bold>p-value</bold>
                            <xref rid="t002fn003" ref-type="table-fn">
                              <sup>
                                <bold>b</bold>
                              </sup>
                            </xref>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 10</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stunted<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1158</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">322 (27.8)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">317 (27.1)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.03 (0.86, 1.24)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.72</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Underweight<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1157</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">93 (8.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">67 (5.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.44 (1.04, 1.99)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.03</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ &lt; -2<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1158</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">89 (7.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1168</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">88 (7.5)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.02 (0.75, 1.39)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.89</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 26</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stunted</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1150</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">258 (22.4)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1162</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">214 (18.4)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.28 (1.05, 1.57)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.02</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Underweight<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1151</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">81 (7.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1161</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">63 (5.4)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.32 (0.94, 1.85)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.11</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ &lt; -2<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1151</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">19 (1.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1162</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">17 (1.5)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.13 (0.58, 2.19)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.72</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 74</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stunted<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">864</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">305 (35.3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">879</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">281 (32.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.16 (0.95, 1.42)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.14</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Underweight<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">864</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">79 (9.1)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">878</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">50 (5.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.67 (1.15, 2.41)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ &lt; -2<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">863</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">20 (2.3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">879</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">18 (2.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.13 (0.60, 2.16)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.70</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Week 104</td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Stunted<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">655</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">228 (34.8)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">215 (32.9)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.09 (0.87, 1.37)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.47</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">Underweight<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">654</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">54 (8.3)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">31 (4.7)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">1.81 (1.14, 2.85)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1"> </td>
                          <td align="left" style="background-color:#FFFFFF" rowspan="1" colspan="1">HCAZ &lt; -2<sup>†</sup></td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">655</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">12 (1.8)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">653</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">13 (2.0)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.92 (0.42, 2.03)</td>
                          <td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">0.83</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Stunted—length-for-age WHO z-score more than 2 standard deviations below reference population mean; Underweight—weight-for-age WHO z-score more than 2 standard deviations below reference population mean; Odds Ratio (95% CI) is from logistic regression</p>
                    </fn>
                    <fn id="t002fn002">
                      <p><sup>a</sup> p-value from student’s t-test</p>
                    </fn>
                    <fn id="t002fn003">
                      <p><sup>b</sup> p-value from Wald X<sup>2</sup> test; <sup>†</sup>Post-hoc analysis.</p>
                    </fn>
                    <fn id="t002fn004">
                      <p><underline><italic toggle="yes">Abbreviations</italic></underline>: <italic toggle="yes">HCAZ—head circumference-for-age z-score; iNVP—infant nevirapine prophylaxis; LAZ—length-for-age z-score; mART—maternal antiretroviral treatment; N—number; SE—standard error; WAZ—weight-for-age z-score; %—percent; 95% CI—95% confidence interval</italic>.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>There were no differences between the mART and iNVP arms for the primary outcome measure’s mean LAZ at week 26 (p-value = 0.39) or any of the secondary growth outcomes at this time point (all p-values ≥0.18) (<xref rid="pone.0255250.g002" ref-type="fig">Fig 2</xref>).</p>
                <fig position="float" id="pone.0255250.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0255250.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Infant growth outcomes by assigned study arm.</title>
                  </caption>
                  <graphic xlink:href="pone.0255250.g002" position="float"/>
                </fig>
                <p>At week 26, in primary analysis, the mean (95% CI) LAZ was -0.90 (-0.99, -0.81) in the mART arm compared to -0.85 (-0.93, -0.76) in the iNVP arm, for a mean difference of -0.05 (-0.18, 0.07). At week 26, the secondary analysis mean WAZ and HCAZ were not different, with mean difference (95% CI) of 0.00 (-0.09, 0.10) in WAZ and -0.07 (-0.18, 0.04) in HCAZ, (p-values = 0.96 and 0.18, respectively). There was no evidence that the postpartum randomization ARV exposure effect on LAZ at week 26 differed by country of residence (p-value = 0.23), <italic toggle="yes">in utero</italic> ARV exposure (p-value = 0.47), or breastfeeding status (p-value = 0.56). Among infants breast feeding at Week 26 the mean (95% CI) difference in LAZ was -0.04 (-0.16, 0.08). At weeks 74 and 104, the mART and iNVP arms did not differ in secondary analyses of mean LAZ, WAZ or HCAZ.</p>
                <p>Stunting (LAZ more than two SD below the WHO Child Growth Standards mean in the reference population) at weeks 10, 26, 74 and 104 in the mART arm versus the iNVP arm was measured in 28% vs 27%, 22% vs 18%, 35% vs 32%, and 35% vs 33% infants, respectively. At week 26, infants assigned to the mART arm were more likely to be stunted compared to those randomized to the iNVP arm (OR 1.28 (95%CI 1.05, 1.57), p-value = 0.017, secondary analysis). <italic toggle="yes">Post hoc</italic> analyses revealed no differences in stunting at weeks 10, 74 and 104 with 443/1308 (34%) of infants being stunted at week 104. Underweight scores (WAZ more than two SD below the WHO Child Growth Standards median for that population) at weeks 10, 26, 74 and 104 in the mART arm versus the iNVP arm were observed in 8% vs 6%, 7% vs 5%, 9% vs 6% and 8% vs 5% infants, respectively. In <italic toggle="yes">post hoc</italic> analyses, infants assigned to mART were more likely to be underweight compared to iNVP infants at each of week 10, 74 and 104 (OR (95% CI): 1.44 (1.04, 1.99), 1.67 (1.15, 2.41) and 1.81 (1.14, 2.85), respectively) and at week 26, but the confidence interval includes no difference at week 26 (OR (95% CI): 1.32 (0.94, 1.85)). Consistent trends were seen for LAZ and WAZ in sensitivity analyses using z-score thresholds of -1 and -3 for LAZ and -1 and 2.5 for WAZ (<xref rid="pone.0255250.s003" ref-type="supplementary-material">S1 Table</xref>). Head circumference measurements revealed no difference in the proportion of infants with HCAZ&lt;-2 between the two study arms (all p-values ≥0.70).</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec017">
              <title>Discussion</title>
              <p>Our data reveal no effect on postnatal infant/child growth of exposure to maternal ART in breastmilk when compared to extended infant NVP prophylaxis in a randomized sample of HIV-exposed and uninfected infants in sub-Saharan Africa and India who breastfed for a median duration of 16 months. These findings are an important addition to the literature in that our analysis from a multi-site randomized clinical trial in resource limited multinational settings examines the effect on growth attributable to maternal ART alone versus extended NVP prophylaxis without added exposure to advanced maternal HIV disease or truncated breastfeeding—a notable gap not addressed in publications before antiretroviral treatment became available [<xref rid="pone.0255250.ref001" ref-type="bibr">1</xref>] and pre-dating the era of universal ART [<xref rid="pone.0255250.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0255250.ref023" ref-type="bibr">23</xref>] when ART was reserved for women with advanced HIV disease. These data are aligned with current literature in the era of universal ART and extended breastfeeding which document suboptimal postnatal growth despite high HIV-free survival when compared to WHO population norms [<xref rid="pone.0255250.ref002" ref-type="bibr">2</xref>] and to HIV unexposed infants [<xref rid="pone.0255250.ref002" ref-type="bibr">2</xref>,<xref rid="pone.0255250.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0255250.ref024" ref-type="bibr">24</xref>].</p>
              <p>Our findings extend what is previously known, that administration of daily infant NVP prophylaxis throughout the duration of breastfeeding has no effect on postnatal infant growth [<xref rid="pone.0255250.ref025" ref-type="bibr">25</xref>], and that lower weight at birth attributable to <italic toggle="yes">in utero</italic> maternal ART vs zidovudine exposure corrects rapidly [<xref rid="pone.0255250.ref022" ref-type="bibr">22</xref>]. While stunting at age 6 months was more common in the mART than iNVP arm in our study, the effect was modest and it is unclear whether the effect is a transient effect. Kapito-Tembo <italic toggle="yes">et al</italic> reported lower LAZ at 6 weeks of age in breastfed infants born to pregnant women with HIV on life-long ART from Malawi’s Option B+ program but no difference in overall anthropometric growth through 18 months of age when compared to infants not exposed to HIV [<xref rid="pone.0255250.ref026" ref-type="bibr">26</xref>]. The retrospective secondary analysis of the combined Mashi and Mma Bana data sets by Powis <italic toggle="yes">et al</italic> [<xref rid="pone.0255250.ref022" ref-type="bibr">22</xref>] also reported differential mean recumbent length in the first few months of life among more than one thousand singleton infants born HIV-uninfected at term and exposed <italic toggle="yes">in utero</italic> to maternal ART vs zidovudine. While mothers receiving ART in these Botswana cohorts had more advanced HIV disease than those receiving zidovudine alone, the authors rightly call for closer scrutiny of biological explanations for this early but persistent effect on infant length.</p>
              <p>Heterogeneity in growth trajectories among breastfed HEUs were described by Lane in Rwanda [<xref rid="pone.0255250.ref002" ref-type="bibr">2</xref>] and Le Roux in South Africa [<xref rid="pone.0255250.ref024" ref-type="bibr">24</xref>]. Characteristics such as maternal height, <italic toggle="yes">in utero</italic> growth restriction, birth weight, birth length and sex were identified as predictive of growth trajectory, most marked for LAZ. In our study, LAZ remained below the WHO standard at all time points and the decline was progressive with age, yet the weight deficit was less marked. As eloquently outlined by Lane [<xref rid="pone.0255250.ref002" ref-type="bibr">2</xref>], maternal ART and extended breastfeeding appear insufficient to sustain normal linear growth of HEUs yet promote adequate weight, resulting in LAZ:WLZ discordance—a combination with unknown impact on long-term health. It is well established that early-life growth and development carry health consequences extending into adulthood, hence the importance of better understanding these observed growth deficits among HEUs in the era of universal ART and extended breastfeeding. Continued study into the underlying mechanisms is needed to inform interventions to address pathways potentially resulting from exposure to maternal HIV and ART toxicities [<xref rid="pone.0255250.ref012" ref-type="bibr">12</xref>].</p>
              <p>Major strengths of our data are that the mothers in PROMISE had high CD4 counts with no advanced HIV disease—almost all were WHO Clinical Stage I. Importantly, maternal ART exposure during pregnancy was randomly assigned, thus decreasing selection bias and minimizing unequal distribution of potential confounders like fetal growth or maternal HIV exposure. Also, breastfeeding duration extended into the second year of life, thus mirroring current infant feeding practice in these settings. However, there were some limitations to the study in that infants included in this analysis excluded those with birth weights below 2000g and the protease inhibitor-based maternal ART regimen assigned in the PROMISE study is not currently widely used. Thus, our findings cannot be generalized to infants of women with HIV receiving other ART regimens or to those with more advance HIV disease than the mothers enrolled in PROMISE. Additionally, our infant follow-up ended at week 104, so we are not able to assess possible longer-term effects of these exposures.</p>
            </sec>
            <sec sec-type="conclusions" id="sec018">
              <title>Conclusion</title>
              <p>Administering universal ART to breastfeeding mothers with HIV does not appear to have a negative effect on their infants’ growth compared to extended infant NVP prophylaxis in follow up through age 104 weeks, although both groups demonstrated decrements in height relative to WHO norms. While resulting in high infant HIV-free survival, initiating maternal ART and extending breastfeeding still falls short of achieving optimal child health for young children living in resource limited international settings and exposed to HIV. Further research is needed to identify the subsets of HEUs at risk of malnutrition, associated factors and strategies to improve infant growth.</p>
            </sec>
            <sec id="sec019" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pone.0255250.s001" position="float" content-type="local-data">
                <label>S1 Checklist</label>
                <caption>
                  <title>CONSORT 2010 checklist of information to include when reporting a randomised trial*.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0255250.s001.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0255250.s002" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>PROMISE trial schema.</title>
                  <p>(TIF)</p>
                </caption>
                <media xlink:href="pone.0255250.s002.tif">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0255250.s003" position="float" content-type="local-data">
                <label>S1 Table</label>
                <caption>
                  <title>Sensitivity analysis comparisons of infant growth measurements by Postpartum Component randomization.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0255250.s003.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0255250.s004" position="float" content-type="local-data">
                <label>S1 PROMISE study protocol</label>
                <caption>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0255250.s004.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>The PROMISE study team gratefully acknowledges the dedication and commitment of the mother-infant pairs and site study teams without whom this study would not have been possible. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, USAID or the United States government. Antiretrovirals were provided free of charge for the PROMISE study by AbbVie, Gilead Sciences, and GlaxoSmithKline.</p>
              <p><bold>PROMISE Study Team Members</bold>: Judith Currier, Katherine Luzuriaga, Adriana Weinberg, James McIntyre, Tsungai Chipato, Karin Klingman, Renee Browning, Mireille Mpoudi-Ngole, Jennifer S. Read, George Siberry, Heather Watts, Lynette Purdue, Terrence Fenton, Linda Barlow-Mosha, Mary Pat Toye, Mark Mirochnick, William B. Kabat, Benjamin Chi, Marc Lallemant, Karin Nielsen; Statistical and Data Analysis Center, Harvard T.H. Chan School of Public Health: Kevin Butler MS, Konstantia Angelidou MS, David Shapiro PHD, and Sean Brummel Ph.D. IMPAACT Operations Center: Anne Coletti, Veronica Toone, Megan Valentine, Kathleen George; Frontier Science Data Management Center: Amanda Zadzilka, Michael Basar, Amy Jennings, Adam Manzella.</p>
              <p><bold>INDIA</bold>. <italic toggle="yes">Byramjee Jeejeebhoy Government Medical College CRS</italic>, <italic toggle="yes">Pune</italic>: Sandesh Patil, MBBS; Ramesh Bhosale, MD; Neetal Nevrekar, MD.</p>
              <p><bold>MALAWI</bold>. <italic toggle="yes">College of Medicine—Johns Hopkins University Project</italic>, <italic toggle="yes">Blantyre</italic>: Salome Kunje, BSc; Alex Siyasiya, Certificate in Microbiology; Mervis Maulidi, Certificate in Nursing and Midwifery. <italic toggle="yes">University of North Carolina Project</italic>, <italic toggle="yes">Lilongwe</italic>: Francis Martinson, MBChB; Ezylia Makina, RNM; Beteniko Milala, BAE.</p>
              <p><bold>SOUTH AFRICA</bold>. <italic toggle="yes">University of KwaZulu-Natal</italic>, <italic toggle="yes">Centre Aids Prevention Research South Africa (CAPRISA)</italic>, <italic toggle="yes">Durban</italic>: Nozibusiso Rejoice Skosana, BN; Sajeeda Mawlana, MBChB. <italic toggle="yes">Family Clinical Research Unit</italic>, Cape Town: Jeanne Louw MSc; Magdel Rossouw MNutr, MBChB; Lindie Rossouw MBChB. <italic toggle="yes">Shandukani CRS</italic>, <italic toggle="yes">Johannesburg</italic>: Masebole Masenya, MD; Janet Grab, BPharm. <italic toggle="yes">Perinatal HIV Research Unit</italic>, <italic toggle="yes">Soweto</italic>: Nasreen Abrahams, MBA; Mandisa Nyati, MBChB; Sylvia Dittmer, MBChB. <italic toggle="yes">Umlazi CRS</italic>, <italic toggle="yes">Durban</italic>: Dhayendre Moodley, MSc, PhD; Vani Chetty, BScHon; Alicia Catherine Desmond, MPharm.</p>
              <p><bold>TANZANIA</bold>. <italic toggle="yes">Kilimanjaro Christian Medical Centre CRS</italic>: Boniface Njau, MPH; Cynthia Asiyo, Bsc; Pendo Mlay, MD.</p>
              <p><bold>UGANDA.</bold><italic toggle="yes">MU-JHU Research Collaboration CRS</italic>, <italic toggle="yes">Kampala</italic>: Maxensia Owor MBChB, Mmed, MPH; Jim Aizire, MBChB, MHS, PhD; Moreen Kamateeka, MBChB, MPH; Dorothy Sebikari MBChB, MPH.</p>
              <p><bold>ZAMBIA.</bold><italic toggle="yes">George Clinic CRS</italic>, <italic toggle="yes">Lusaka</italic>: Felistas M. Mbewe, RN, BSc; Martin Mwalukanga, Diploma in Clinical Medicine; Mwangelwa Mubiana-Mbewe, BSc, MBChB, MMed, MBA; Helen B. Bwalya, BPharm.</p>
              <p><bold>ZIMBABWE.</bold><italic toggle="yes">Harare Family Care CRS</italic>, <italic toggle="yes">Harare</italic>: Tichaona Vhembo, MBChB; Nyasha Mufukari, BPharm. <italic toggle="yes">Seke North CRS</italic>, <italic toggle="yes">Chitungwiza</italic>: Lynda Stranix-Chibanda, MBChB, MMed; Teacler Nematadzira, MBChB, MSc; Gift Chareka, MSc. <italic toggle="yes">St</italic>. <italic toggle="yes">Mary’s CRS</italic>, <italic toggle="yes">Chitungwiza</italic>: Jean Dimairo, BPharm, Tsungai Chipato MBChB, FRCOG, MSc; Bangani Kusakara, MBChB; Mercy Mutambanengwe, BPharm; Emmie Marote, SRN MA.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0255250.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Omoni</surname><given-names>AO</given-names></name>, <name><surname>Ntozini</surname><given-names>R</given-names></name>, <name><surname>Evans</surname><given-names>C</given-names></name>, <name><surname>Prendergast</surname><given-names>AJ</given-names></name>, <name><surname>Moulton</surname><given-names>LH</given-names></name>, <name><surname>Christian</surname><given-names>PS</given-names></name>, <etal>et al</etal>. <source>Child Growth According to Maternal and Child HIV Status in Zimbabwe: The Pediatric Infectious Disease Journal</source>. <year>2017</year><month>Sep</month>;<volume>36</volume>(<issue>9</issue>):<fpage>869</fpage>–<lpage>76</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/INF.0000000000001574</pub-id>
<?supplied-pmid 28198792?><pub-id pub-id-type="pmid">28198792</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Lane</surname><given-names>CE</given-names></name>, <name><surname>Bobrow</surname><given-names>EA</given-names></name>, <name><surname>Ndatimana</surname><given-names>D</given-names></name>, <name><surname>Ndayisaba</surname><given-names>GF</given-names></name>, <name><surname>Adair</surname><given-names>LS</given-names></name>. <article-title>Determinants of growth in HIV-exposed and HIV-uninfected infants in the Kabeho Study</article-title>. <source>Maternal &amp; Child Nutrition</source>. <year>2019</year><month>Jan</month><day>29</day>;<fpage>e12776</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/mcn.12776</pub-id><?supplied-pmid 30609287?><pub-id pub-id-type="pmid">30609287</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Nicholson</surname><given-names>L</given-names></name>, <name><surname>Chisenga</surname><given-names>M</given-names></name>, <name><surname>Siame</surname><given-names>J</given-names></name>, <name><surname>Kasonka</surname><given-names>L</given-names></name>, <name><surname>Filteau</surname><given-names>S</given-names></name>. <article-title>Growth and health outcomes at school age in HIV-exposed, uninfected Zambian children: follow-up of two cohorts studied in infancy</article-title>. <source>BMC pediatrics</source>. <year>2015</year><month>Jun</month><day>6</day>;<volume>15</volume>:<fpage>66</fpage>–<lpage>66</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12887-015-0386-8</pub-id>
<?supplied-pmid 26048411?><pub-id pub-id-type="pmid">26048411</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Muhangi</surname><given-names>L</given-names></name>, <name><surname>Lule</surname><given-names>SA</given-names></name>, <name><surname>Mpairwe</surname><given-names>H</given-names></name>, <name><surname>Ndibazza</surname><given-names>J</given-names></name>, <name><surname>Kizza</surname><given-names>M</given-names></name>, <name><surname>Nampijja</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Maternal HIV infection and other factors associated with growth outcomes of HIV-uninfected infants in Entebbe, Uganda.</article-title><source>Public Health Nutrition</source>. <year>2013</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1548</fpage>–<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1017/S1368980013000499</pub-id>
<?supplied-pmid 23507372?><pub-id pub-id-type="pmid">23507372</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Aizire</surname><given-names>J</given-names></name>, <name><surname>Sikorskii</surname><given-names>A</given-names></name>, <name><surname>Ogwang</surname><given-names>LW</given-names></name>, <name><surname>Kawalazira</surname><given-names>R</given-names></name>, <name><surname>Mutebe</surname><given-names>A</given-names></name>, <name><surname>Familiar-Lopez</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda</article-title>. <source>AIDS (London, England).</source><year>2020</year><month>Feb</month>;<volume>34</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>25</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/QAD.0000000000002405</pub-id>
<?supplied-pmid 31634154?><pub-id pub-id-type="pmid">31634154</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Black</surname><given-names>RE</given-names></name>, <name><surname>Allen</surname><given-names>LH</given-names></name>, <name><surname>Bhutta</surname><given-names>ZA</given-names></name>, <name><surname>Caulfield</surname><given-names>LE</given-names></name>, <name><surname>de Onis</surname><given-names>M</given-names></name>, <name><surname>Ezzati</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Maternal and child undernutrition: global and regional exposures and health consequences</article-title>. <source>The Lancet</source>. <year>2008</year><month>Jan</month><day>19</day>;<volume>371</volume>(<issue>9608</issue>):<fpage>243</fpage>–<lpage>60</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61690-0</pub-id>
<?supplied-pmid 18207566?><pub-id pub-id-type="pmid">18207566</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Black</surname><given-names>RE</given-names></name>, <name><surname>Victora</surname><given-names>CG</given-names></name>, <name><surname>Walker</surname><given-names>SP</given-names></name>, <name><surname>Bhutta</surname><given-names>ZA</given-names></name>, <name><surname>Christian</surname><given-names>P</given-names></name>, <name><surname>de Onis</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Maternal and child undernutrition and overweight in low-income and middle-income countries</article-title>. <source>The Lancet</source>. <year>2013</year><month>Aug</month>;<volume>382</volume>(<issue>9890</issue>):<fpage>427</fpage>–<lpage>51</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60937-X</pub-id>
<?supplied-pmid 23746772?><pub-id pub-id-type="pmid">23746772</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Olofin</surname><given-names>I</given-names></name>, <name><surname>McDonald</surname><given-names>CM</given-names></name>, <name><surname>Ezzati</surname><given-names>M</given-names></name>, <name><surname>Flaxman</surname><given-names>S</given-names></name>, <name><surname>Black</surname><given-names>RE</given-names></name>, <name><surname>Fawzi</surname><given-names>WW</given-names></name>, <etal>et al</etal>. <article-title>Associations of Suboptimal Growth with All-Cause and Cause-Specific Mortality in Children under Five Years: A Pooled Analysis of Ten Prospective Studies</article-title>. <source>PLOS ONE</source>. <year>2013</year><month>May</month><day>29</day>;<volume>8</volume>(<issue>5</issue>):<fpage>e64636</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0064636</pub-id><?supplied-pmid 23734210?><pub-id pub-id-type="pmid">23734210</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Grantham-McGregor</surname><given-names>S</given-names></name>, <name><surname>Cheung</surname><given-names>YB</given-names></name>, <name><surname>Cueto</surname><given-names>S</given-names></name>, <name><surname>Glewwe</surname><given-names>P</given-names></name>, <name><surname>Richter</surname><given-names>L</given-names></name>, <name><surname>Strupp</surname><given-names>B</given-names></name>. <article-title>Developmental potential in the first 5 years for children in developing countries</article-title>. <source>The Lancet</source>. <year>2007</year><month>Jan</month><day>6</day>;<volume>369</volume>(<issue>9555</issue>):<fpage>60</fpage>–<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60032-4</pub-id>
<?supplied-pmid 17208643?><pub-id pub-id-type="pmid">17208643</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Hofer</surname><given-names>CB</given-names></name>, <name><surname>Keiser</surname><given-names>O</given-names></name>, <name><surname>Zwahlen</surname><given-names>M</given-names></name>, <name><surname>Lustosa</surname><given-names>CS</given-names></name>, <name><surname>Frota</surname><given-names>ACC</given-names></name>, <name><surname>de Oliveira</surname><given-names>RH</given-names></name>, <etal>et al</etal>. <article-title>In Utero Exposure to Antiretroviral Drugs: Effect on Birth Weight and Growth Among HIV-exposed Uninfected Children in Brazil.</article-title><source>The Pediatric Infectious Disease Journal</source> [Internet]. <year>2016</year>;<volume>35</volume>(<issue>1</issue>). Available from: <ext-link xlink:href="https://journals.lww.com/pidj/Fulltext/2016/01000/In_Utero_Exposure_to_Antiretroviral_Drugs___Effect.14.aspx" ext-link-type="uri">https://journals.lww.com/pidj/Fulltext/2016/01000/In_Utero_Exposure_to_Antiretroviral_Drugs___Effect.14.aspx</ext-link>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/INF.0000000000000926</pub-id>
<?supplied-pmid 26741583?><pub-id pub-id-type="pmid">26741583</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Himes</surname><given-names>SK</given-names></name>, <name><surname>Wu</surname><given-names>JW</given-names></name>, <name><surname>Jacobson</surname><given-names>DL</given-names></name>, <name><surname>Tassiopoulos</surname><given-names>K</given-names></name>, <name><surname>Hazra</surname><given-names>R</given-names></name>, <name><surname>Kacanek</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected Children.</article-title><source>The Pediatric Infectious Disease Journal</source> [Internet]. <year>2015</year>;<volume>34</volume>(<issue>8</issue>). Available from: <ext-link xlink:href="https://journals.lww.com/pidj/Fulltext/2015/08000/Meconium_Tenofovir_Concentrations_and_Growth_and.13.aspx" ext-link-type="uri">https://journals.lww.com/pidj/Fulltext/2015/08000/Meconium_Tenofovir_Concentrations_and_Growth_and.13.aspx</ext-link>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/INF.0000000000000747</pub-id>
<?supplied-pmid 25961889?><pub-id pub-id-type="pmid">25961889</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Wedderburn</surname><given-names>CJ</given-names></name>, <name><surname>Evans</surname><given-names>C</given-names></name>, <name><surname>Yeung</surname><given-names>S</given-names></name>, <name><surname>Gibb</surname><given-names>DM</given-names></name>, <name><surname>Donald</surname><given-names>KA</given-names></name>, <name><surname>Prendergast</surname><given-names>AJ</given-names></name>. <article-title>Growth and Neurodevelopment of HIV-Exposed Uninfected Children: a Conceptual Framework.</article-title><source>Curr HIV/AIDS Rep</source>. <year>2019</year><month>Dec</month>;<volume>16</volume>(<issue>6</issue>):<fpage>501</fpage>–<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11904-019-00459-0</pub-id>
<?supplied-pmid 31732866?><pub-id pub-id-type="pmid">31732866</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Alvarez-Uria</surname><given-names>G</given-names></name>, <name><surname>Midde</surname><given-names>M</given-names></name>, <name><surname>Pakam</surname><given-names>R</given-names></name>, <name><surname>Bachu</surname><given-names>L</given-names></name>, <name><surname>Naik</surname><given-names>PK</given-names></name>. <article-title>Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India</article-title>. <source>ISRN Pediatr</source>. 2012/06/03 ed. <year>2012</year>;<volume>2012</volume>:<fpage>763591</fpage>–<lpage>763591</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5402/2012/763591</pub-id>
<?supplied-pmid 22701801?><pub-id pub-id-type="pmid">22701801</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Thior</surname><given-names>I</given-names></name>, <name><surname>Lockman</surname><given-names>S</given-names></name>, <name><surname>Smeaton</surname><given-names>LM</given-names></name>, <name><surname>Shapiro</surname><given-names>RL</given-names></name>, <name><surname>Wester</surname><given-names>C</given-names></name>, <name><surname>Heymann</surname><given-names>SJ</given-names></name>, <etal>et al</etal>. <article-title>Breastfeeding Plus Infant Zidovudine Prophylaxis for 6 Months vs Formula Feeding Plus Infant Zidovudine for 1 Month to Reduce Mother-to-Child HIV Transmission in Botswana: A Randomized Trial: The Mashi Study</article-title>. <source>JAMA</source>. <year>2006</year><month>Aug</month><day>16</day>;<volume>296</volume>(<issue>7</issue>):<fpage>794</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.296.7.794</pub-id><?supplied-pmid 16905785?><pub-id pub-id-type="pmid">16905785</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref015">
                <label>15</label>
                <mixed-citation publication-type="other">World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and prevention HIV infection, reccomendations for a public health approach, second edition [Internet]. 2016 [cited 2017 Aug 30]. Available from: <ext-link xlink:href="http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1" ext-link-type="uri">http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0255250.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Flynn</surname><given-names>PM</given-names></name>, <name><surname>Taha</surname><given-names>TE</given-names></name>, <name><surname>Cababasay</surname><given-names>M</given-names></name>, <name><surname>Fowler</surname><given-names>MG</given-names></name>, <name><surname>Mofenson</surname><given-names>LM</given-names></name>, <name><surname>Owor</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE).</article-title><source>JAIDS Journal of Acquired Immune Deficiency Syndromes</source>. <year>2018</year><month>Apr</month>;<volume>77</volume>(<issue>4</issue>):<fpage>383</fpage>–<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/QAI.0000000000001612</pub-id>
<?supplied-pmid 29239901?><pub-id pub-id-type="pmid">29239901</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Fowler</surname><given-names>M</given-names></name>, <name><surname>Qin</surname><given-names>M</given-names></name>, <name><surname>Fiscus</surname><given-names>S</given-names></name>, <name><surname>Currier</surname><given-names>J</given-names></name>, <name><surname>Flynn</surname><given-names>P</given-names></name>, <name><surname>Chipato</surname><given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention</article-title>. <source>The New England journal of medicine</source>. <year>2016</year><month>Nov</month><day>3</day>;<volume>375</volume>(<issue>18</issue>):<fpage>1726</fpage>–<lpage>37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa1511691</pub-id>
<?supplied-pmid 27806243?><pub-id pub-id-type="pmid">27806243</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Hoffman</surname><given-names>RM</given-names></name>, <name><surname>Angelidou</surname><given-names>KN</given-names></name>, <name><surname>Brummel</surname><given-names>SS</given-names></name>, <name><surname>Saidi</surname><given-names>F</given-names></name>, <name><surname>Violari</surname><given-names>A</given-names></name>, <name><surname>Dula</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial</article-title>. HIV Clinical Trials. <year>2018</year><month>Nov</month><day>2</day>;<volume>19</volume>(<issue>6</issue>):<fpage>209</fpage>–<lpage>24</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/15284336.2018.1537327</pub-id>
<?supplied-pmid 30890061?><pub-id pub-id-type="pmid">30890061</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><collab>INSIGHT START Study Group</collab>, <name><surname>Lundgren</surname><given-names>J</given-names></name>, <name><surname>Babiker</surname><given-names>A</given-names></name>. <article-title>Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection</article-title>. <source>N Engl J Med</source>. <year>2015</year><month>Jul</month><day>20</day>;<volume>373</volume>(<issue>9</issue>):<fpage>795</fpage>–<lpage>807</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa1506816</pub-id>
<?supplied-pmid 26192873?><pub-id pub-id-type="pmid">26192873</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><collab>World Health Organisation</collab>. <article-title>WHO Anthro for personal computers, version 3.2.2, 2011: Software for assessing growth and development of the world’s children [Internet].</article-title> Geneva; <year>2010</year>. Available from: <ext-link xlink:href="http://www.who.int/childgrowth/software/en/" ext-link-type="uri">http://www.who.int/childgrowth/software/en/</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0255250.ref021">
                <label>21</label>
                <mixed-citation publication-type="book"><collab>World Health Organisation</collab>. <chapter-title>Nutrition Landscape Information System (NLIS) country profile indicators: interpretation guide [Internet].</chapter-title><publisher-name>WHO Document Production Services</publisher-name>, <publisher-loc>Geneva, Switzerland</publisher-loc>; <year>2010</year> [cited 2021 Apr 27]. Available from: <ext-link xlink:href="https://www.who.int/nutrition/nlis_interpretation_guide.pdf" ext-link-type="uri">https://www.who.int/nutrition/nlis_interpretation_guide.pdf</ext-link>.</mixed-citation>
              </ref>
              <ref id="pone.0255250.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Powis</surname><given-names>KM</given-names></name>, <name><surname>Smeaton</surname><given-names>L</given-names></name>, <name><surname>Ogwu</surname><given-names>A</given-names></name>, <name><surname>Lockman</surname><given-names>S</given-names></name>, <name><surname>Dryden-Peterson</surname><given-names>S</given-names></name>, <name><surname>van Widenfelt</surname><given-names>E</given-names></name>, <etal>et al</etal>. <source>Effects of in Utero Antiretroviral Exposure on Longitudinal Growth of HIV-Exposed Uninfected Infants in Botswana: JAIDS Journal of Acquired Immune Deficiency Syndromes</source>. <year>2011</year><month>Feb</month>;<volume>56</volume>(<issue>2</issue>):<fpage>131</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/QAI.0b013e3181ffa4f5</pub-id>
<?supplied-pmid 21124227?><pub-id pub-id-type="pmid">21124227</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Morden</surname><given-names>E</given-names></name>, <name><surname>Technau</surname><given-names>K-G</given-names></name>, <name><surname>Giddy</surname><given-names>J</given-names></name>, <name><surname>Maxwell</surname><given-names>N</given-names></name>, <name><surname>Keiser</surname><given-names>O</given-names></name>, <name><surname>Davies</surname><given-names>M-A</given-names></name>. <article-title>Growth of HIV-Exposed Uninfected Infants in the First 6 Months of Life in South Africa: The IeDEA-SA Collaboration.</article-title><name><surname>Nixon</surname><given-names>DF</given-names></name>, editor. <source>PLoS ONE</source>. <year>2016</year><month>Apr</month><day>6</day>;<volume>11</volume>(<issue>4</issue>):<fpage>e0151762</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0151762</pub-id><?supplied-pmid 27049853?><pub-id pub-id-type="pmid">27049853</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>le Roux</surname><given-names>SM</given-names></name>, <name><surname>Abrams</surname><given-names>EJ</given-names></name>, <name><surname>Donald</surname><given-names>KA</given-names></name>, <name><surname>Brittain</surname><given-names>K</given-names></name>, <name><surname>Phillips</surname><given-names>TK</given-names></name>, <name><surname>Nguyen</surname><given-names>KK</given-names></name>, <etal>et al</etal>. <article-title>Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study</article-title>. <source>The Lancet Child &amp; Adolescent Health</source>. <year>2019</year><month>Apr</month>;<volume>3</volume>(<issue>4</issue>):<fpage>234</fpage>–<lpage>44</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S2352-4642(19)30007-0</pub-id>
<?supplied-pmid 30773459?><pub-id pub-id-type="pmid">30773459</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0255250.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Onyango–Makumbi</surname><given-names>C</given-names></name>, <name><surname>Owora</surname><given-names>AH</given-names></name>, <name><surname>Mwiru</surname><given-names>RS</given-names></name>, <name><surname>Mwatha</surname><given-names>A</given-names></name>, <name><surname>Young</surname><given-names>AM</given-names></name>, <name><surname>Moodley</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>EXTENDED PROPHYLAXIS WITH NEVIRAPINE DOES NOT AFFECT GROWTH IN HIV-EXPOSED INFANTS</article-title>: <source>JAIDS Journal of Acquired Immune Deficiency Syndromes</source>. <year>2019</year><month>Sep</month>;<fpage>1</fpage>.</mixed-citation>
              </ref>
              <ref id="pone.0255250.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Kapito-Tembo</surname><given-names>AP</given-names></name>, <name><surname>Bauleni</surname><given-names>A</given-names></name>, <name><surname>Wesevich</surname><given-names>A</given-names></name>, <name><surname>Ongubo</surname><given-names>D</given-names></name>, <name><surname>Hosseinipour</surname><given-names>MC</given-names></name>, <name><surname>Dube</surname><given-names>Q</given-names></name>, <etal>et al</etal>. <article-title>Growth and neurodevelopment outcomes in HIV, tenofovir and efavirenz exposed breastfed infants in PMTCT Option B+ program in Malawi.</article-title><source>JAIDS Journal of Acquired Immune Deficiency Syndromes [Internet].</source><year>2020</year><month>Oct</month><day>5</day> [cited 2020 Oct 11];Publish Ahead of Print. Available from: <ext-link xlink:href="https://journals.lww.com/10.1097/QAI.0000000000002515" ext-link-type="uri">https://journals.lww.com/10.1097/QAI.0000000000002515</ext-link>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article article-type="aggregated-review-documents" id="pone.0255250.r001" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Socio</surname>
                    <given-names>Giuseppe Vittorio</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Giuseppe Vittorio De Socio</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Giuseppe Vittorio De Socio</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj001" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">9 Apr 2021</named-content>
              </p>
              <p>PONE-D-21-06961</p>
              <p>Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Stranix-Chibanda,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>You will see that the Referees found your work of some interest. However, they also raised major criticisms. Please respond to all the comments by Reviewers 1 and 2.</p>
              <p>Please submit your revised manuscript by May 15 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Giuseppe Vittorio De Socio, MD, PhD</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>When submitting your revision, we need you to address these additional requirements.</p>
              <p>
                <list list-type="order">
                  <list-item>
                    <p>Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
                  </list-item>
                </list>
              </p>
              <p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> and</p>
              <p>
                <ext-link xlink:href="about:blank" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
              </p>
              <p>
                <list list-type="order">
                  <list-item>
                    <p>Please provide the names of the 14 health facility-based research sites related to the study.</p>
                  </list-item>
                </list>
              </p>
              <p>
                <list list-type="order">
                  <list-item>
                    <p>We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</ext-link>.</p>
                  </list-item>
                </list>
              </p>
              <p>In your revised cover letter, please address the following prompts:</p>
              <p>3a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p>
              <p>3b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <ext-link xlink:href="http://www.bmj.com/content/340/bmj.c181.long" ext-link-type="uri">http://www.bmj.com/content/340/bmj.c181.long</ext-link> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <ext-link xlink:href="http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories" ext-link-type="uri">http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories</ext-link>.</p>
              <p>We will update your Data Availability statement on your behalf to reflect the information you provide.</p>
              <p>
                <list list-type="order">
                  <list-item>
                    <p>Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <ext-link xlink:href="http://journals.plos.org/plosone/s/supporting-information" ext-link-type="uri">http://journals.plos.org/plosone/s/supporting-information</ext-link>.</p>
                  </list-item>
                </list>
              </p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>2. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>3. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>4. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>5. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: Abstract</p>
              <p>- report the exact p-value instead of p-value≥0.16 in line 65 and p-value≥0.09 in line 67 and anywhere else in the manuscript, unless p-value is less than 0.001 or greater than 0.999.</p>
              <p>Statistical methods</p>
              <p>- t-tests to compare z-scores doesn't seem appropriate here; why not conduct an analysis of covariance (ANCOVA) by fitting a linear regression model of the post-randomisation z-scores adjusting for baseline/pre-randomisation z-scores and with treatment group-time interaction to estimate how the z-scores differ between groups at the various post-intervention times when they were measured. A likelihood ratio p-value for the treatment-time interaction would assess evidence for whether the treatments differ at the various time points - this would be a statistically more efficient way to analyse these data.</p>
              <p>Results</p>
              <p>- rather than presenting means and confidence intervals, I think table 2 should present means and SEs for each treatment group, followed by the difference, confidence intervals and p-values, for each outcome and time.</p>
              <p>- actual p-values should be reported all through unless less than 0.001 or greater than 0.999; for example for p≥0.14 in line 323 and p≤0.03 in line 329</p>
              <p>Reviewer #2: The article is generally well written with impressive design and study size. The article is generally well analyzed and presented. Except some few sentences I generally agree with the interpretations and summaries.</p>
              <p>The conclusion in the abstract is emphasizing stunting and underweight “differences”. Based on the data you present, there seems to be no difference at week 0, week 10, week 74 and week 104 (and no clinically relevant difference at week 26). I highly doubt the 0.9% “difference” at 26 weeks which is not seen earlier or later is causally related to the intervention/drugs. Rather, I find it more probable to assume that this is due to either slight measurement inaccuracies or stochastic effects in timing of growth (as growth velocity is not constant). Thus, I suggest the conclusion in the abstract is modified, e.g. as following:</p>
              <p>“In HEUs, growth effects from postnatal exposure to mART compared to iNVP were comparable for measures on length, weight and head-circumference with no clinically relevant differences between the groups. “</p>
              <p>Similarly, with so comparable mean WAZ-measures between the groups, I am also skeptical to the interpretation of difference for underweight. This could be e.g. a threshold effect. If you check two additional thresholds (e.g. -1 and -3) and find similar differences, I would be a little less skeptical to the validity of these differences. As there are multiple comparisons and the study have considerable power and size, you could consider using a p&lt;0.01 significance threshold. More importantly, I would recommend that you emphasize clinically relevant differences rather than statistically significant differences. Thus, the subsequent sentences in the conclusion of the abstract should be aligned with the manuscript, and I would slightly modified the results section accordingly.</p>
              <p>I think the first sentence of the discussion and the conclusion in the main manuscript is more balanced.</p>
              <p>Except these essential changes, I find the article excellent and well worth publishing.</p>
              <p>**********</p>
              <p>6. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: <bold>Yes: </bold>Lars T. Fadnes</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pone.0255250.r002">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r002</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 0</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj002" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">11 May 2021</named-content>
              </p>
              <p>REVIEWER #1: </p>
              <p>R1.1 - Abstract - report the exact p-value instead of p-value≥0.16 in line 65 and p-value≥0.09 in line 67 and anywhere else in the manuscript, unless p-value is less than 0.001 or greater than 0.999.</p>
              <p>Thank you for the comment. We have revised the Abstract [see lines 66 and 68] to show that the several p-values presented there were all &gt;=0.16 and &gt;=0.09, respectively, and trust that this adequately addresses the concern raised. </p>
              <p>R1.2 - Statistical methods - t-tests to compare z-scores doesn't seem appropriate here; why not conduct an analysis of covariance (ANCOVA) by fitting a linear regression model of the post-randomisation z-scores adjusting for baseline/pre-randomisation z-scores and with treatment group-time interaction to estimate how the z-scores differ between groups at the various post-intervention times when they were measured. A likelihood ratio p-value for the treatment-time interaction would assess evidence for whether the treatments differ at the various time points - this would be a statistically more efficient way to analyse these data.</p>
              <p>We understand the approach suggested by Reviewer 1, however, the protocol-specified primary objective was to conduct a cross sectional comparison at postpartum Week 26, with the primary outcome measure of LAZ. Other timepoints and measures were secondary. After discussion by the writing team, we decided to clarify the statistical analysis approach in the revised text [see Statistical Methods lines 221-225 and Abstract line 57] and believe that the explanation is now clear. </p>
              <p>R1.3 - Results - rather than presenting means and confidence intervals, I think table 2 should present means and SEs for each treatment group, followed by the difference, confidence intervals and p-values, for each outcome and time.</p>
              <p>Table 2 has been adjusted in line with Reviewer 1’s comment and week 0 infant anthropometric measures were moved to Table 1 [see lines 300-309 in the revised manuscript]. Please note that we took the opportunity to correct an erroneous percentage for stunting in Table 2. The text preceding the table, table title, and footnote were updated accordingly. Table 1 was updated thus: addition of week 0 LAZ, WAZ, and HCAZ under infant characteristics (including % z score &lt; -2); removal of rows for “N” for maternal characteristics (since they are redundant given the column headers and # missing); addition of 10%-90% for infant characteristics (to be consistent with the descriptive statistics presented for mothers); footnote updated accordingly [see lines 271-279].</p>
              <p>R1.4 - Results - actual p-values should be reported all through unless less than 0.001 or greater than 0.999; for example for p≥0.14 in line 323 and p≤0.03 in line 329</p>
              <p>We have attempted to address this concern by clarifying that we present several p-values in the examples mentioned where no actual p-value is shown. Please see the inserted text in the revised manuscript [for example in line 333]. </p>
              <p>REVIEWER #2: </p>
              <p>R2.0 - The article is generally well written with impressive design and study size. The article is generally well analyzed and presented. Except some few sentences I generally agree with the interpretations and summaries.</p>
              <p>Thank you for the comment.</p>
              <p>R2.1 - The conclusion in the abstract is emphasizing stunting and underweight “differences”. Based on the data you present, there seems to be no difference at week 0, week 10, week 74 and week 104 (and no clinically relevant difference at week 26). I highly doubt the 0.9% “difference” at 26 weeks which is not seen earlier or later is causally related to the intervention/drugs. Rather, I find it more probable to assume that this is due to either slight measurement inaccuracies or stochastic effects in timing of growth (as growth velocity is not constant). Thus, I suggest the conclusion in the abstract is modified, e.g. as following:</p>
              <p>“In HEUs, growth effects from postnatal exposure to mART compared to iNVP were comparable for measures on length, weight and head-circumference with no clinically relevant differences between the groups. “</p>
              <p>Thank you for the insight and the suggested revision which was considered by the writing team. We opted to use the sentence you provided for the Conclusion in the Abstract [see lines 71-82 in the revised manuscript].</p>
              <p>R2.2A - Similarly, with so comparable mean WAZ-measures between the groups, I am also skeptical to the interpretation of difference for underweight. This could be e.g. a threshold effect. If you check two additional thresholds (e.g. -1 and -3) and find similar differences, I would be a little less skeptical to the validity of these differences.</p>
              <p>We hope the adjusted interpretation presented in the revised manuscript likely addresses this concern. To explain the -2 SD threshold selection, that is the standard clinical definition for stunting and underweight based on World Health Organisation definitions and is not driven by study data. Thus, we made minor clarifications to the Methods and inserted new reference #21 to illustrate the basis for that threshold in the revised manuscript [see lines 237—239]. However, we did carry out a sensitivity analysis around -2, with thresholds of -1.9 and -2.1 to address potential random noise right around this measurement that could result in disproportionate assignments to one category. Results were very similar, and we determined there was no need to include them in the manuscript.</p>
              <p>R2.2B - As there are multiple comparisons and the study have considerable power and size, you could consider using a p&lt;0.01 significance threshold. </p>
              <p>Indeed, this study does have considerable size. The 0.05 significance level was pre-specified in our analysis plan.</p>
              <p>R2.2C - More importantly, I would recommend that you emphasize clinically relevant differences rather than statistically significant differences. Thus, the subsequent sentences in the conclusion of the abstract should be aligned with the manuscript, and I would slightly modified the results section accordingly.</p>
              <p>We agree with Reviewer 2’s helpful guidance. Accordingly, we revised the Conclusions in the Abstract [see lines 71-82] and removed the term ‘significant’ from several sentences in the Results section [see lines 314-346] to remove any misrepresentation of clinical relevance. We do include p-values in Table 2, as suggested by Reviewer 1 (comment R1.3), but they are not emphasized heavily in the text.</p>
              <p>R2.2D - I think the first sentence of the discussion and the conclusion in the main manuscript is more balanced.</p>
              <p>Except these essential changes, I find the article excellent and well worth publishing.</p>
              <p>Thank you for the insightful comments and suggestions which we have taken on board and used to strengthen the manuscript we now resubmit.</p>
              <p>EDITOR'S COMMENTS</p>
              <p>These have been attended to within the cover letter, as instructed.</p>
              <p>There are no supplemental files for this submission -- the protocol and COSORT checklist were submitted as supplemental files after the initial package was uploaded following guidance.</p>
              <supplementary-material id="pone.0255250.s005" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers_PONE-D-21-06961 [R1].pdf</named-content></p>
                </caption>
                <media xlink:href="pone.0255250.s005.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="aggregated-review-documents" id="pone.0255250.r003" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r003</article-id>
              <title-group>
                <article-title>Decision Letter 1</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Socio</surname>
                    <given-names>Giuseppe Vittorio</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Giuseppe Vittorio De Socio</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Giuseppe Vittorio De Socio</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj003" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>1</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">8 Jun 2021</named-content>
              </p>
              <p>PONE-D-21-06961R1</p>
              <p>Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial</p>
              <p>PLOS ONE</p>
              <p>Dear Dr. Stranix-Chibanda,</p>
              <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
              <p>We invite you to submit a revised version of the manuscript that addresses  minor suggestions by Reviewer #1 and #2.</p>
              <p>Please submit your revised manuscript by 30 June 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
              <p>Please include the following items when submitting your revised manuscript:</p>
              <p>
                <list list-type="bullet">
                  <list-item>
                    <p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p>
                  </list-item>
                  <list-item>
                    <p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p>
                  </list-item>
                  <list-item>
                    <p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p>
                  </list-item>
                </list>
              </p>
              <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
              <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
              <p>We look forward to receiving your revised manuscript.</p>
              <p>Kind regards,</p>
              <p>Giuseppe Vittorio De Socio, MD, PhD</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
              <p>[Note: HTML markup is below. Please do not edit.]</p>
              <p>Reviewers' comments:</p>
              <p>Reviewer's Responses to Questions</p>
              <p>
                <bold>Comments to the Author</bold>
              </p>
              <p>1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.</p>
              <p>Reviewer #1: All comments have been addressed</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>2. Is the manuscript technically sound, and do the data support the conclusions?</p>
              <p>The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>3. Has the statistical analysis been performed appropriately and rigorously? </p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: Yes</p>
              <p>**********</p>
              <p>4. Have the authors made all data underlying the findings in their manuscript fully available?</p>
              <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>5. Is the manuscript presented in an intelligible fashion and written in standard English?</p>
              <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.</p>
              <p>Reviewer #1: Yes</p>
              <p>Reviewer #2: (No Response)</p>
              <p>**********</p>
              <p>6. Review Comments to the Author</p>
              <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)</p>
              <p>Reviewer #1: Please correct the typographical error at the top of page 11 of 24 - you mean Kruskal-Wallis, not Kruskal-Wallace.</p>
              <p>Reviewer #2: I think the article has improved and that the first response is fine. I do not fully agree with the approaches on question 2.2, but that being said the discussion of that finding and conclusion still look generally fine. I am aware that z-score -2 is a commonly used threshold for stunting and underweight, but e.g. -3 is also a commonly used threshold for severe underweight/stunting. See also the article by Briend et al. on arguments for not only focusing on a single threshold (Briend A, Van den Broeck J, Fadnes LT: Target weight gain for moderately wasted children during supplementation interventions - a population-based approach. Public health nutrition 2011:1-7.) I do not see the option of adding sensitivity analysis for z-score thresholds of -1.9 and -2.1 (which is very close to the original analysis) as good alternatives to what I suggested of a sensitivity analyses with z-score thresholds of -3 and -1. Unless you see similar results with thresholds of -3 and -1, I think the presentation of differences in the results section is not optimal. However, if you show similar trends for sensitivity analyses, you will probably convince me of your presentation/interpretation. For the results section as I consider the confidence intervals for the dichotomous outcomes are relatively wide (stunting/overweight), I suggest sensitivity analysis with thresholds further away from the original analysis (and that these preferable are added as a supplementary table) to guide whether these are threshold effects. If so, that could be mentioned shortly in the results/discussion section. Also a note relating to the p-value threshold, even though p&lt;0.05 was predefined, it is still possible to guide interpretation not only dichotomously but to discuss degree of association (and chance of random associations versus causal inferences).</p>
              <p>That being said, the study and article is generally very good and well worth publishing. I just think adding a sensitivity analysis which is more different from the original analysis would lift the paper even more.</p>
              <p>**********</p>
              <p>7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
              <p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
              <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.</p>
              <p>Reviewer #1: No</p>
              <p>Reviewer #2: <bold>Yes: </bold>Lars Fadnes</p>
              <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
              <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
            </body>
          </sub-article>
          <sub-article article-type="author-comment" id="pone.0255250.r004">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r004</article-id>
              <title-group>
                <article-title>Author response to Decision Letter 1</article-title>
              </title-group>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj004" related-article-type="editor-report"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>2</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="author-response-date">30 Jun 2021</named-content>
              </p>
              <p>REVIEWER #1: </p>
              <p>[Revision 1] R1.1 - Please correct the typographical error at the top of page 11 of 24 - you mean Kruskal-Wallis, not Kruskal-Wallace.</p>
              <p>Thank you for identifying this error which is corrected in line 228 of the marked-up revised manuscript [Revision 2]. </p>
              <p>REVIEWER #2: </p>
              <p>[Revision 1] R2.0 - I think the article has improved and that the first response is fine. </p>
              <p>Noted.</p>
              <p>[Revision 1] R2.1 - I do not fully agree with the approaches on question 2.2, but that being said the discussion of that finding and conclusion still look generally fine. I am aware that z-score -2 is a commonly used threshold for stunting and underweight, but e.g. -3 is also a commonly used threshold for severe underweight/stunting. See also the article by Briend et al. on arguments for not only focusing on a single threshold (Briend A, Van den Broeck J, Fadnes LT: Target weight gain for moderately wasted children during supplementation interventions - a population-based approach. Public health nutrition 2011:1-7.) I do not see the option of adding sensitivity analysis for z-score thresholds of -1.9 and -2.1 (which is very close to the original analysis) as good alternatives to what I suggested of a sensitivity analyses with z-score thresholds of -3 and -1. Unless you see similar results with thresholds of -3 and -1, I think the presentation of differences in the results section is not optimal. However, if you show similar trends for sensitivity analyses, you will probably convince me of your presentation/interpretation. For the results section as I consider the confidence intervals for the dichotomous outcomes are relatively wide (stunting/overweight), I suggest sensitivity analysis with thresholds further away from the original analysis (and that these preferable are added as a supplementary table) to guide whether these are threshold effects. If so, that could be mentioned shortly in the results/discussion section. </p>
              <p>The writing team accepted the reviewer’s comment and are grateful for the reference provided. We agree with not focusing on a single threshold for this secondary outcome measure. We conducted additional sensitivity analyses using thresholds further away from the original z-score threshold (-2.0). For length-for-age (LAZ), the thresholds used were -1.0 and -3.0, as suggested. However, the number of infants with weight-for-age (WAZ) below -3.0 was very low (&lt;2%) at all time points, therefore the thresholds used for WAZ were -1.0 and -2.5. The direction of the odds ratio estimate remains consistent across the different thresholds for both LAZ and WAZ. The results of this sensitivity analysis are now mentioned in line 333 of the marked-up revised manuscript [Revision 2]. The sensitivity analysis results are uploaded with this rebuttal letter for review. We have included a table as new Supporting Information for the revised manuscript (caption inserted at the end of the manuscript document), and include figures below illustrating additional thresholds for the LAZ and WAZ comparisons (Figure A and Figure B - uploaded in the separate document Response to Reviewers). </p>
              <p>[Revision 1] R2.2 - Also a note relating to the p-value threshold, even though p&lt;0.05 was predefined, it is still possible to guide interpretation not only dichotomously but to discuss degree of association (and chance of random associations versus causal inferences).</p>
              <p>That being said, the study and article is generally very good and well worth publishing. I just think adding a sensitivity analysis which is more different from the original analysis would lift the paper even more.</p>
              <p>We reviewed the manuscript with this note in mind. In Revision 2, we removed “significant” from the Abstract and Results in lines 64 and 304, and p-values in lines 70 and 325. Upon review, we revised lines 359-360 in the Discussion that appeared to rely too heavily on the p-values. </p>
              <p>Figure A. Sensitivity of odds ratio estimate to varying length-for-age Z-score (LAZ) binary categorization</p>
              <p>Figure B. Sensitivity of odds ratio estimate to varying weight-for-age Z-score (WAZ) binary categorization</p>
              <supplementary-material id="pone.0255250.s006" position="float" content-type="local-data">
                <label>Attachment</label>
                <caption>
                  <p>Submitted filename: <named-content content-type="submitted-filename">Response to Reviewers [R2].pdf</named-content></p>
                </caption>
                <media xlink:href="pone.0255250.s006.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pone.0255250.r005" specific-use="decision-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r005</article-id>
              <title-group>
                <article-title>Decision Letter 2</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Socio</surname>
                    <given-names>Giuseppe Vittorio</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Giuseppe Vittorio De Socio</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Giuseppe Vittorio De Socio</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj005" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>2</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">13 Jul 2021</named-content>
              </p>
              <p>Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial</p>
              <p>PONE-D-21-06961R2</p>
              <p>Dear Dr. Stranix-Chibanda,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Giuseppe Vittorio De Socio, MD, PhD</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Additional Editor Comments (optional):</p>
              <p>Reviewers' comments:</p>
            </body>
          </sub-article>
          <sub-article article-type="editor-report" id="pone.0255250.r006" specific-use="acceptance-letter">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0255250.r006</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>De Socio</surname>
                    <given-names>Giuseppe Vittorio</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Giuseppe Vittorio De Socio</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Giuseppe Vittorio De Socio</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0255250" id="rel-obj006" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">4 Aug 2021</named-content>
              </p>
              <p>PONE-D-21-06961R2 </p>
              <p>Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial </p>
              <p>Dear Dr. Stranix-Chibanda:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Giuseppe Vittorio De Socio </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
